文献速递流行病学与生物统计临床试验与 GCP

创伤后下肢制动患者静脉血栓栓塞事件的预防:系统综述与网络Meta分析及元流行病学方法

Prevention of venous thromboembolic events in patients with lower leg immobilization after trauma: Systematic review and network meta-analysis with meta-epsidemiological approach.
PubMed 文献 · PLoS Med · 2022-07-18

该系统综述与贝叶斯网络Meta分析纳入14项研究共8198例下肢创伤后临时制动患者,评估药物性血栓预防的疗效与安全性。与对照组相比,利伐沙班、磺达肝癸钠和低分子量肝素均与主要静脉血栓栓塞风险显著降低相关,且未观察到主要出血风险增加。利伐沙班在疗效和净临床获益方面排名最高的可能性最大。

要点

  • 利伐沙班、磺达肝癸钠和低分子量肝素均与主要静脉血栓栓塞风险显著降低相关,且未增加主要出血风险。
  • 利伐沙班在疗效和净临床获益方面排名最高的可能性最大。
  • 该网络Meta分析确认下肢创伤后制动患者血栓预防具有有利的获益/风险比,利伐沙班的证据等级最高。

核心结论

  • 该网络Meta分析确认下肢创伤后制动患者血栓预防具有有利的获益/风险比,利伐沙班的证据等级最高。

研究设计与样本

  • 系统综述与贝叶斯网络Meta分析,纳入所有比较药物性血栓预防与安慰剂或无治疗的随机试验,检索Medline、Embase和Web of Science至2021年7月。
  • 纳入14项研究共8198例患者,包括成人孤立性下肢损伤需临时制动(保守或手术治疗)并评估药物性血栓预防剂或安慰剂或无治疗的研究。
  • 主要终点为主要静脉血栓栓塞(近端深静脉血栓、症状性静脉血栓栓塞和肺栓塞相关死亡)的发生率。

主要发现

  • 与对照组相比,利伐沙班、磺达肝癸钠和低分子量肝素与主要静脉血栓栓塞风险显著降低相关,比值比分别为0.02(95%可信区间0.00至0.19)、0.22(95%可信区间0.06至0.65)和0.32(95%可信区间0.15至0.56)。
  • 两种治疗均未观察到主要出血风险增加。
  • 利伐沙班在疗效和净临床获益方面排名最高的可能性最大。

局限性

  • 主要局限性在于网络中间接比较与直接比较数量相同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lower limb trauma requiring immobilization is a significant contributor to overall venous thromboembolism (VTE) burden. The clinical effectiveness of thromboprophylaxis for this indication and the optimal agent strategy are still a matter of debate. Our main objective was to assess the efficacy of pharmacological thromboprophylaxis to prevent VTE in patients with isolated temporary lower limb immobilization after trauma. We aimed to estimate and compare the clinical efficacy and the safety of the different thromboprophylactic treatments to determine the best strategy. METHODS AND FINDINGS: We conducted a systematic review and a Bayesian network meta-analysis (NMA) including all available randomized trials comparing a pharmacological thromboprophylactic treatment to placebo or to no treatment in patients with leg immobilization after trauma. We searched Medline, Embase, and Web of Science until July 2021. Only RCT or observational studies with analysis of confounding factors including adult patients requiring temporary immobilization for an isolated lower limb injury treated conservatively or surgically and assessing pharmacological thromboprophylactic agents or placebo or no treatment were eligible for inclusion. The primary endpoint was the incidence of major VTE (proximal deep vein thrombosis, symptomatic VTE, and pulmonary embolism-related death). We extracted data according to Preferred Reporting Items for Systematic Reviews and Meta-analyses for NMA and appraised selected trials with the Cochrane review handbook. Fourteen studies were included (8,198 patients). Compared to the control group, rivaroxaban, fondaparinux, and low molecular weight heparins were associated with a significant risk reduction of major VTE with an odds ratio of 0.02 (95% credible interval (CrI) 0.00 to 0.19), 0.22 (95% CrI 0.06 to 0.65), and 0.32 (95% CrI 0.15 to 0.56), respectively. No increase of the major bleeding risk was observed with either treatment. Rivaroxaban has the highest likelihood of being ranked top in terms of efficacy and net clinical benefit. The main limitation is that the network had as many indirect comparisons as direct comparisons. CONCLUSIONS: This NMA confirms the favorable benefit/risk ratio of thromboprophylaxis for patients with leg immobilization after trauma with the highest level of evidence for rivaroxaban. TRIAL REGISTRATION: PROSPERO CRD42021257669.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Douillet D, Chapelle C, Ollier E, et al. Prevention of venous thromboembolic events in patients with lower leg immobilization after trauma: Systematic review and network meta-analysis with meta-epsidemiological approach. PLoS Med. 2022. PMID: 35849624. doi:10.1371/journal.pmed.1004059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。